Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings
CNBC Earnings
Barrons Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

Stocktwits
MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-

Cymabay Therapeutics | CBAY

Daily Technical Analysis of Cymabay Therapeutics

Cymabay Therapeutics moved up less than 1% today. The market isn't being very decisive in its valuation of Biotechnology company.

The Biotechnology company isn't at an immediate support or resistance level that might be predictive. But let's also consider momentum! Cymabay Therapeutics has had a nice run over the last year and provided good returns to shareholders. Over the previous year, the Biotechnology company has grown 269.51 percent which isn't too bad. CBAY might find some support at the 32.21 level, buyers might push the price back up from here. But it's not very clear what will happen.


Last analyzed on 2024-03-17

Analyst Ratings for Cymabay Therapeutics By Price Target And Rating

The analysts have a very negative view on Cymabay Therapeutics, they are seeing negative things in the fundamentals and operation of the company. The current Analysts Sentiment Score is -278.02. Most companies range between (-200 to 200).

Here's a break down of the latest rating changes. On 2024-02-29 HC Wainwright reiterated their rating of Neutral and added a price target of $32.50. On 2024-02-20 there was confirmation of the previous rating by SVB Leerink which was Outperform and they set their price target at $32.50. UBS Group reiterated a rating of Buy on 2024-02-14 and also increased their price target by 30% to $32.50. On 2024-02-14 there was a downgrade announced by Lifesci Capital from Outperform to Market Perform. Piper Sandler reiterated a rating of Overweight on 2024-02-14 and decided to decrease their price target by -1.52% down to $32.50. Raymond James downgraded from Outperform to Market Perform on 2024-02-13 and added a price target of $32.50. On 2024-02-13 B. Riley reiterated their rating of Buy and moved up their price target to $32.50 which is a 12.07% increase. Cantor Fitzgerald released a downgrade on 2024-02-13 from Overweight to Neutral and they set their price target at $32.50. On 2024-02-13 there was confirmation of the previous rating by Jonestrading which was Buy . On 2024-02-13 there was confirmation of the previous rating by BTIG Research which was Buy .

Company Ratings Score ?
Composite analyst sentiment score
Positive Ratings Negative Ratings Boost Price Target Lower Price Target
CBAY-278.027.74-624.9563.09-1.93

Earnings Per Share (EPS) Estimates By Year and Quarter

(updated 2024-03-02)
Company YOY Growth Score (typical -20 to +20) Revision Directions (-6 to +6)
CBAY0.000.00

Short interest for Cymabay Therapeutics

We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.

Company Short Score (typical 1-15) ?
We take into account several different measures and attributes of short interest to create a composite sentiment score. typical range (0 - 30)
Short Interest Days to Cover Rate of Change Shares Short
CBAY8.51%9.31925526.26810500000

How Cymabay Therapeutics compares to the broader Healthcare sector and the more specific Biotechnology industry

Segment Count 1 Day% 5 Day 1 Month 3 Month 6 Month 1 Year RSI 3mo S-momo ? 6mo S-momo 1yr S-momo Resistance ? Support Demark Sell ? Demark Buy Short Interest Analysts Ratings ?
Biotechnology

Show Me Companies With:

S-Momentum: Highest | Lowest
1 Day Growth: Highest | Lowest
5 Day Growth: Highest | Lowest
1 Month Growth: Highest | Lowest
6 Month Growth: Highest | Lowest
1061.830.09-2.3011.0537.8734.0537.8634.1814.9613.67-13850.04-11280.963.3023.589.5571.69
Healthcare

Show Me Companies With:

S-Momentum: Highest | Lowest
1 Day Growth: Highest | Lowest
5 Day Growth: Highest | Lowest
1 Month Growth: Highest | Lowest
6 Month Growth: Highest | Lowest
2492.020.520.296.2824.4020.6641.7731.7711.2311.41-12872.42-11623.084.9217.176.9351.90

Social Sentiment for Cymabay Therapeutics

Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.

Ticker Social Sentiment(1-10)
CBAY

Companies with the highest correlation to Cymabay Therapeutics

Company Score 1 Day% 5 Day 1 Month 3 Month 6 Month 1 Year RSI 3mo S-momo ? 6mo S-momo 1yr S-momo Resistance ? Support Demark Sell ? Demark Buy Short Interest Score
SDGR | Schrodinger, Inc. Common 0.613.82-3.204.60-24.20-2.609.6841-9.59-8.05-8.61-7848.89-3412.90009.02067
INSM | Insmed, Inc.0.591.113.72-1.44-8.755.4862.62317.289.3544.47-3030.47-14664.07009.8069
SAGE | Sage Therapeutics, Inc0.562.26-4.66-11.36-15.30-10.65-54.4327-22.06-22.77-15.93-51237.60-1298.120012.6533
PACB | Pacific Biosciences of Ca0.555.68-3.12-32.73-61.21-55.50-59.2627-93.79-62.33-71.02-58610.720.000014.0556
ACCD | Accolade, Inc. Common Sto0.520.302.46-2.54-17.51-6.72-23.5133-1.13-0.552.67-13860.57170.04004.61812

Top 3 correlating companies

See full charts for all peers

Sentiment Score

How to use: use the research links to research the asset. Then simply type in a score for each category between (01, 02, 03, 04, 05). 05 being the most bullish and 01 being the most bearish. It will automatically calculate the average and combine it with the technical score to create an overall score to rank prospects by. You can also type notes into each field.

Earnings Estimates
Analyst Rating
Price Targets
Short Interest
Financials
Options Sentiment
Institutional Ownership
Social Sentiment
Fidelity Summary
Overall Summary Notes
Calculated Sentiment Sum

Score Sum
(1-45)

/

Average
(1-5)

+

Pattern Rank
(1-5)

=

Total Score
(1-10)

Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-